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1 INTRODUCTION 
One third of the world’s population is though to be infected with Mycobacterium 
tuberculosis, the bacteria that cause tuberculosis (TB). For the majority the infection will 
stay dormant through out their lifetime. But for people living under poor conditions or in 
areas with high prevalence of immune suppressive conditions as for example malnutrition 
and HIV, the infection can develop into active TB. Although TB is a curable disease 8.8 
million new cases of active TB occurs every year together with almost 2 million TB related 
deaths worldwide – primarily in the poorest communities of the developing world (Dye & 
Floyd 2006: 290, WHO/TDR 2006: 8). 
Despite major advances in technology over the last two decades, most health care 
providers around the world still rely on simple but inaccurate diagnostic tests for both 
active and latent tuberculosis (WHO/TDR 2006: 9). The current goal standards of TB 
diagnostics are still difficult to apply in many developing countries as the methods are 
costly and acquire advanced laboratory technology often not available in resource-limited 
settings. Today there is a growing international focus on the importance of developing new 
diagnostic methods, anti-TB drugs and vaccines. Both the World Health Organization and 
the Stop TB Partnerships has implemented research in development of these as a part of 
their strategies to fight global TB (Stop TB Partnership: 4,6).  
With basis in existing diagnostic tests of latent tuberculosis infections (LTBI), a team of 
researchers at Hvidovre Hospital has developed a new novel test. The aim is to develop a 
test that is more accurate, easier to use in resource-limited setting and cheaper to perform. 
Thus contributing to the development of technics that can help control and fight the TB-
epidemic. Developing new diagnostics tools takes time and requires furrow testing, to 
ensure the accuracy and efficiency of the test. This internship report aims to evaluate the 
potential of the new diagnostic test for LTBI developed at Hvidovre Hospital. The report 
will focus on the clinical as well as the socio-economic potential of the test, and the 
findings will be evaluated in relation to the context in which the clinical testing has taken 
place and the tests overall long-term potential. 
A list of glossaries and abbreviations can be found in appendix I. 
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2 THE INTERNSHIP AND ITS OBJECTIVES 
The internship has taken place at the Clinical Research Centre at Hvidovre Hospital, 
Copenhagen. Here a team of researchers, PhD students and medical student are working on 
developing a more accurate and easier to use test for latent tuberculosis infections (LTBI). 
The use of inaccurate diagnostic test for both active and latent tuberculosis is a great 
challenge in many developing countries today in fighting TB. The team at Hvidovre 
Hospital has developed a novel generation of the interferon-γ release assays (IGRA), 
which is though to be the currently most accurate tests for diagnostic of LTBI. By using 
the alternative biomarker IP-10 to detect TB-immune response in individuals, the novel 
test opens up for more accurate diagnostics with higher sensitivity. Applying IP-10 also 
permits the use of the dried blood spots on filter paper, a method that can make the new 
test simpler and cheaper to perform (Ruhwald et al. 2012: 175-176, 182). The test is still 
undergoing optimization, but the long-term objective is to develop a test that can easily be 
applied in resource limited setting in developing countries and contribute to control and 
fight the TB-epidemic.  
The internship took place from the beginning of March 2012 till the end of July 2012, with 
a two-month stay in Cairo, Egypt, from the middle of May till the middle of July. The 
purpose of this stay was to examine the clinical potential of the novel test in relevant 
endemic settings, using patients with confirmed TB diagnosis. Collaboration was 
established with researches at the Molecular Immunology Unit (MIU) at Al-Azhar 
University, Cairo. The partners at the MIU provided laboratory facilities and helped 
establish contact and negotiate an agreement for inclusion of patients from the nearby 
Abbassia Chest Hospital. 
2.1 The internships tasks 
The main objective of the internship has been to perform a clinical testing of the novel IP-
10 test in relevant settings, and evaluate the clinical and contextual potential of the test. 
Working as a part of the TB research team the content of internship has involved 
participation in the planning of the clinical trial in Cairo. Apart from assisting in practical 
preparations and fundraising in Denmark the main task of the internship has been to plan, 
organize and perform the clinical testing of the IP-10 test in Cairo. The intern has 
undertaken the responsibility of coordinating patient inclusion and sample collection with 
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the involved partners at Abbasia Chest Hospital and the MIU at Al-Azhar University. The 
intern has been responsible for processing blood samples in the laboratory facilities at 
MIU, Al-Azhar University and finally collecting and processing data. The intern has been 
working under the supervision of MD PhD Morten Ruhwald, head of the TB research team 
at Hvidovre Hospital. 
2.2 Objectives 
The main objective of this internship report is to examine the potential of the IP-10 test to 
contribute to the control and fighting of TB in a developing country such as Egypt and 
evaluate the research performed during the internship.  
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3 METHODS  
The evaluation of the IP-10 test is done on the basis of results from previous studies and 
preliminary data from the clinical testing in Cairo. Beside clinical data, some of the socio-
economic factors influencing TB control in Egypt were exanimated. This was done 
through interviews with TB professionals in Egypt and data from the World Health 
Organization (WHO) and the National TB Control Programme (NTP) in Egypt.    
3.1 First hand empiric data 
3.1.1 Clinical testing 
To examine the clinical potential of the IP-10 test a clinical trial has been performed in 
collaboration with Al-Azhar University, Ain Shams University and Abbasia Chest Hospital 
in Cairo. During the period from the middle of May till the middle of July 36 TB patients 
were included in the clinical trial. All patients were included from Abbasia Chest Hospital, 
from the following inclusion criteria. 1) A confirmed TB-diagnosis. Diagnoses were 
confirmed initially by smear microscopy and x-ray and later backed up by BACTEC 
culture and MOTT identification test, to confirm the infection with M.tuberculosis. All 
diagnostic tests were performed in the laboratory facilities of Abbasia Chest Hospitals. 2) 
The patients should not have received more than four weeks of anti-TB treatment. In the 
same time period 11 healthy control individuals were included among students and staff at 
the Al-Azhar and Ain Shams University. 
1x10 mL blood was collected from each patient and control in 10 evacuated blood 
collection tubes, each containing either TB-antigen, a mitogen (pos. control) or heparin 
(neg. control) see figure 1A. Patient samples where collected by educated staff at the 
Abbasia Chest Hospital, trained and instructed under the authority of Dr. Faten Aly 
Shoukry, Lab Director according to a sample collection protocol found in appendix II. 
Skilled staff at the Al-Azhar and Ain Shams University collected the control samples under 
the supervision of the intern. The Clinical Research Centre at Hvidovre Hospital provided 
evacuated blood collection tubes together with needles for sample collection. 
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The intern processed the blood samples at the MIU laboratory at Al-Azhar University. 
Whole blood was dripped onto filter paper and dried (figure 1B), samples were then 
centrifuged and the plasma of the samples were extracted for later plasma ELISA (figure 
1C). The dried blood spots on filter paper will later be transported to Denmark for filter 
paper ELISA analysis, and compared with the result of the plasma ELISA performed in 
Egypt. The protocols for the processing of the samples can be found in appendix III. 
As it was not possible to include an efficient amount of patients and controls during the 
period of pre-assessed time period, it was decided to prolong the study training an 
Egyptian biotechnology student to proceed the work. The biotechnology student was 
trained by the intern and took over the work of collecting and processing the samples, 
when the intern left Cairo in the middle of July. A furrow analysis of the clinical data has 
not yet been conducted, why the usage of the data will be limited in this report. The final 
analysis of the data is expected performed when the study ends in September, October 
2012.  
A	   B	  
C	  
Figure 1: A) Evacuated blood collection tubes. Tube 1 and 8 (negative controls) only contains 
heparin, which prevents blood clothing. Tube 2, 3, 4, 5, 6 and 9 (test) contains heparin and 
different combinations of TB-antigen that will stimulate immune response, and excretion of IP-10 
in the blood’s cells if the person is infected with TB. Tube 7 and 10 (positive control) contains 
heparin and the mitogen PHA, which will stimulate an immune response unrelated to infection. B) 
Dried blood spots on filter paper. C) Optical density reader for ELISA analysis, used for 
quantification of specific proteins (IP-10) in the blood sample. 
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3.1.2 Interviews 
To gain knowledge about challenges of controlling and fighting TB in Egypt and the 
challenges of working with TB research in developing, semi structured interviews were 
conducted with Danish and Egyptian TB-professionals. Prior to the stay in Egypt, two 
interviews were conducted with Danish doctors, Michala Rose and Thomas Nørrelykke 
Nissen, with experience in working with TB in Tanzania. The focus of these interviews 
was the challenges of fighting and controlling TB in developing countries and challenges 
of conducting research in a developing country. During the stay in Cairo one interview was 
conducted with Asharf Abdelhassib, head of MDR-TB at Abbasia Chest Hospital. Another 
interview was scheduled with Prof. Nabila El-Sheik, head of the MIU at Al-Azhar 
University, but was rescheduled and took place after the interns return to Denmark, using a 
skype connection. The three other interviews were done in face-to-face meetings.  
All interviews were recorded, though in the interview with Michala Rose the recorder 
failed to save the interview. The two interviews with Prof. Nabila El-Sheikh and Asharf 
Abdelhassib have been transcribed in their full length. The interview with Thomas 
Nørrelykke Nissen has been partially transcribed, as only some parts of the interview were 
found relevant for the report. The transcribed interviews can be found in appendix V. 
3.2 Second hand empiric data 
For the analysis, reports and data from the WHO and NTP in Egypt have been used to 
provide an overview of the global and national impact of TB, together with national and 
international strategic plans for fighting TB. A number of different studies concerning TB 
research in developing countries have also been used as references. 
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4 BACKGROUND 
4.1 Tuberculosis 
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium 
tuberculosis. Most common is pulmonary TB, which affects the lungs. Less common is 
extra-pulmonary TB, which accounts for 10-30 of the disease and affects for example 
bones or other organs in the body (Dye & Floyd: 290). Though global incidence rates of 
TB has been falling since 2002, together with the total number of TB cases and deaths 
caused by TB, 8,8 million cases of active TB and around 1,5 million TB related deaths 
were reported in 2010 by the WHO. The majority of active TB cases are found in 
developing countries and although TB is a curable disease it is still a major global health 
issue. Especially TB diagnostics and control of multidrug-resistant TB (MDR-TB) remains 
a great challenge (WHO 2011: 1). 
TB is spread through the air when people with active pulmonary TB expel the bacteria, by 
coughing, talking, spitting etc. (WHO 2011: 3). Only around 10% of the people infected 
with M. tuberculosis will develop active TB, while the rest will carry the bacteria as a 
latent infection. Children have a greater risk of developing active TB than adult, which 
decreases with age  (Dye & Floyd 2006: 290). Also in people living with HIV the risk of 
developing active TB is significantly higher and the high prevalence of TB in African 
countries is strongly link to the presence of the HIV-epidemic (WHO/TDR 2006: 22). 
4.1.1 International strategies to fight tuberculosis 
In the middle of 1990’s the WHO introduced the Directly Observed Therapy – Short 
Course (DOTS) as a strategy to fight TB globally. The original DOTS-strategy consists of 
five key components. 1) Political commitment, 2) early case detections through quality 
assured diagnosis, 3) standardized treatment with supervision and patient support, 4) drug 
supply management system and 5) monitoring and evaluation. Today DOTS is widely used 
and recognized as the international recommended strategy to fight TB, implemented in 
more than 180 countries and with more than 41 millions successfully treated cases globally 
since 1995 (Stop TB Partnership: 26-27). 
When the Millennium Development Goals were launched in 2000 by the United Nations, 
one of the goals was to halt and begin to reverse the incidence of malaria and other major 
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diseases by 2015, including TB (WHO 2011: 3). These goals where later back up by 
another strong international player in the fight against TB, the Stop TB Partnership. The 
multi-sectorial partnership, established in 2000, sat the goal of reducing the prevalence and 
deaths of TB by 50% in 2015, compared to levels of 1990 and eliminate TB as a global 
public health problem by 2050 (Stop TB Partnership: 3). 
In 2006, WHO launched the Stop TB strategy with the purpose of enhancing and 
supporting the DOTS-strategy. The strategies six elements focuses on 1) pursuing high-
quality DOTS expansion and enhancement, 2) addressing TB/HIV co-infections, MDR-TB 
and vulnerable populations, 3) contribution to strengthen health care system, 4) engaging 
all care providers, 5) empower people and communities with TB and finally 6) enable and 
promote TB research. Same year the Stop TB Partnership launched the Global Plan to Stop 
TB 2006-2015. This plan backs up the Stop TB Strategy by setting a number of specific 
goals for scaling up prevention, treatment and research and securing global funding (Stop 
TB Partnership: 6). Focusing on laboratory strengthening, the Global Plan to Stop TB 
2006-2015 sat the goals of a global TB case detection rate of 84 %, a treatment success 
rate of 87 % and HIV testing of 85 % of all TB patients by 2015. Also by 2015 the goal is 
to develop a new point-of-care test for active TB and a test allowing effective detection of 
latent TB infections. Together with the development of new anti-TB drugs enabling 
treatment programs of 1-2 months duration and a new safe and effective vaccine (Stop TB 
Partnership: 6, 17). The partnership states that the development of such measures is 
essential for the goal of elimination TB as a public health issue by 2050 to be achieved 
(Stop TB Partnership: 56). 
4.1.2 Diagnostics and treatment of active tuberculosis 
Worldwide the most common method for diagnosing active TB is sputum smear 
microscopy, where bacteria are observed in sputum samples examined under a microscope. 
The method was developed more than 100 years ago and is cheap to perform, but 
experience a number of challenges. The test has low sensitivity (40-60%) and is ineffective 
in children and people with extra-pulmonary TB who are not able to produce sputum 
containing the bacilli, and in people infected with HIV (WHO/TDR 2006: 8, 35). In setting 
with more developed laboratory capacity, TB may also be diagnosed by the more accurate 
culture method. But because of general inadequacy of laboratory capacity in many 
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developing countries such test have not been implemented to any significant degree, as it is 
more costly and advance to use (WHO 2011: 2, WHO/TDR 2006: 15). Several other 
methods of TB diagnostics exist, one of the more common being x-ray. 
TB is treated using a combination of different anti-TB drugs, using first line drugs thorugh 
a period of six month around 90 % of TB cases can be cured (Stop TB Partnership: 1). 
Treatment of MDR-TB requires second or third line drugs and is more challenging and 
expensive and can be prolonge up till 2 years. Cure rates for MDR-TB is estimated to 50-
70 % (Stop TB Partnership: 1). The bacillus Calmette-Guérin (BCG) vaccine is the only 
current vaccine against TB. The vaccine is primarily used in small children, where if offers 
some protection against TB, but in adults the vaccine is not very effective (WHO/TDR 
2006: 22).  
4.1.3 Latent tuberculosis infections  
It is estimated that one third of the worlds population is infected with M.tuberculosis. The 
latent infection is difficult to detect as it does not generate any symptoms. Though only 
10% of the infected will develop active TB, poor living conditions and immune 
compromising factors as HIV increase risks of developing active TB. This is also some the 
factors responsible for the rapid progression of TB prevalence seen in the African and 
some Asian regions, where the prevalence of latent TB is estimated to 50-90%. Identifying 
and treating LTBI can reduce the number of active TB, cases as it will reduce the human 
reservoir of infection (WHO/TDR 2006: 22-23). But reducing the reservoir requires time 
and more effective diagnostic tools than the ones available today (Stop TB Partnership: v).  
Diagnosis of latent tuberculosis infections 
In many high-burden countries, the diagnosis and treatment of LTBI receives little priority 
(Abu-Taleb 2010: 751). Until recently the tuberculin skin test (TST) was the only test for 
LTBI (Ruhwald et al. 2012: 175). Tuberculin (proteins from heat-killed M. tuberculosis) is 
injected under the skin. In individuals priory infected with TB the tuberculin will cause a 
hypersensitivity reaction of the skin. The reaction can be observed 24-48 hours after 
injection (WHO/TDR 2006: 41), see figure 2. The TST is greatly challenged on specificity, 
especially in people with BCG vaccine and people with HIV. The IFN-γ release assays 
(IGRAs), considered to be the current state-of-the-art test for LTBI, were developed only 
one decade ago. The IGRAs use cell-mediates immune response to detect LTBI. By 
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stimulating blood samples with TB-antigens, an immune response can be detected by the 
presence of cell-signaling protein that can be quantified using the so-called ELISA 
analysis, figure 2. One the great advantages of the IGRAs is that they are not affected by 
BCG vaccine in the same way as the TST. The IGRAs have also shown to have a higher 
sensitivity in people with HIV (Ruhwald et a. 2012: 176-177).  
 
4.2 The IP-10 test  
Though the IGRA tests have improved LTBI diagnostics on a number of levels, the tests 
still faces some challenges and further improvement of the test is still needed for achieving 
efficient diagnostics. 
4.2.1 IP-10 as an alternative marker 
In 2006 the TB research team at Hvidovre Hospital screened a series of small cell-
signaling proteins for their potential as markers of cell mediated immune response to 
specific M. tuberculosis antigens. The chemokine IP-10 was found to be expressed in very 
high amounts in patients with active TB and not in unexposed controls. IP-10 is express by 
so-called antigen-presenting cells when M. tuberculosis-specific peptides are recognized 
by the immune system. IP-10 is expressed in much higher levels than IFN-γ used in 
IGRAs, which makes it a promising alternative marker. The higher levels make it essayer 
to differentiate positive and negative results in an quantification of the protein, which can 
possibly will generate a higher specificity in the test (Ruhwald et al. 2012: 176). In a series 
Figure 2. The tuberculin skin test, injection (A) and measuring (B). The IFN-γ release assay, 
blood collection tubes, negative control, antigen test and positive control (C) and ELISA 
analysis (D). 
A	   B	   C	   D	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of studies IP-10 has been tested against the IFN-γ. These studies have shown a comparable 
accuracy between the two and indications that IP-10 may perform better in children and 
HIV infected patients (Ruhwald et al. 2012: 178-180). 
4.2.2 The filter paper method 
One of the disadvantages of IGRAs is that they require direct access to laboratory facilities 
that can perform ELISA, or a cold chain for transporting samples to the laboratory. This 
may limit the use of the test in resource limiting settings. Here the higher levels of IP-10 
offer an advantage as it enables quantification of the protein from a smaller amount of 
sample material. This allows the use of dried blood spots on filter paper. The IP-10 protein 
is stable in dried blood, which allows it to be transported over great distances, for example 
by mail, without any need for cooling. This opens up the possibility of a point-of-care test, 
as laboratory analysis can be perform in centralized laboratory facilities without the need 
of patients going there (Ruhwald et al. 2012: 182). 
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5 THEORY 
5.1 Economic, cultural and social challenges of fighting TB in developing 
countries 
As stated in the previous chapter insufficient and expensive diagnostics tools, is one of the 
many challenges of fighting TB. But inadequate technology is fare from the only challenge 
of fighting and controlling the disease. Several economic, geographical, social and cultural 
challenges can be identified, which together with co-morbidities as HIV and an emerging 
prevalence of MDR-TB complicates the diagnostics and treatment of TB. Using Pierre 
Bourdieu’s theory of economic, cultural and social capital, this report tries to categorize 
and map some of these challenges. In Bourdieu’s theory of capitals, economical capital 
refers to the economical and material resources available. The cultural capital is referring 
to qualities such as education and the ability to understand and master social and cultural 
codes. Finally social capital refers to the resources an individual holds due to it’s 
participation in specific social groups and networks such as family, local community etc. 
(Järvinen 2007: 352). 
Many people in developing countries experience some form of economical barriers in 
connection to receiving health care. Costs related to consultation, health service fees, 
transport to health facilities and loss of income and productivity time all challenge the 
patient in a economic capital perspective. Even though free anti-TB drugs are a part of the 
DOTS-strategy, some TB patients still experience having to pay for test and other services  
(WHO 2005: 22-23). TB is often seen in individuals and communities with a low 
economic capital, as TB is a disease strongly associated with poverty. In poor communities 
with malnutrition, unhealthy and crowded living, poor air circulation and poor sanitation 
the probability of TB infections increases (WHO/TDR 2006: 22-23). In some countries 
poor infrastructure can also delay or prevent diagnostics and treatment. Again this relates 
to costs of transportation, which can be a great challenge to people living in rural or remote 
areas. Fighting TB also requires sufficient national capital to support health facilities and 
health care system (WHO, 2005: 28). 
In developing countries TB is often connected to stigma, as a result of poor knowledge and 
incorrect perceptions and ideas about TB. Overcoming stigma therefore requires some 
portion of cultural capital in the form of education and knowledge. Not only for the 
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individual patient but also for the surrounding community. Lack of knowledge about 
symptoms and the importance of quick diagnostic and treatment, can lead to delay in 
treatment and enable further spread if the patient does not take the required precautions 
(WHO 2005: 25-26). Knowledge of TB in the community minimizes risk of rejection of 
the patient from the community. Social rejection equals loss of social capital for the 
individual. Loosing social capital can make it even more difficult for the patient to 
overcome the disease, without support from family and local environment. Danish doctor 
Thomas Nørrelykke Nissen points out the long treatment period for TB as a great 
challenge for many patients, as it can be difficult to uphold compliance for the whole six 
months of the treatment (APP. VI Nissen: 2). National cultural capital is also required to 
overcome the challenges of TB. Sufficient educated health staff is essential to ensure 
effective response to the TB-problem. Interviews conducted with PHC staff in Tanzania, 
concerning diagnostics of TB in children, revealed that many of the health care workers 
felt that they lacked supervision and training in diagnosing TB in children and called for 
better tools and guidelines to assist them in their work (Bjerrum et al. 2012: 2). 
5.2 Conducting medical research in developing countries 
When conducting research in a developing country there are often a number of different 
issues that have to be deal with. This can be practical challenges regarding facilities or 
equipment, or social and cultural issues, challenges regarding language barriers etc. Issues 
of ethics are also often discussed when dealing with research in developing countries. The 
following chapter seeks to explore some of these different challenges. 
Research done in a developing country should demonstrate recognition of and respect for 
the host community’s values, culture and social practices. Coming from a different culture 
it can be difficult to identify acceptable, as certain behavior can be perceived acceptable in 
one culture and unacceptable or insulting in another (Emanual et al. 2004: 932, 934). 
Language barriers, causing poor communicating or misunderstanding between involved 
partners, can also challenge the research.   
Working in developing countries and often having less resources you must be prepared to 
face a some practical challenges. Facilities, equipment and time schedules can show to be 
inadequate and force you to change plans. Thomas Nørrelykke Nissen is a Danish doctor, 
who has work with TB in Tanzania. Among the challenges he experience in connection to 
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his research, he emphasize on time management as being one of the major issues. He 
explains that things often end up taking twice the time expected, due to unexpected 
challenges often of practical nature, for example linked to the functionality of equipment. 
He believes that these types of unforeseen challenges increase the deeper you move into 
the countryside of developing countries. As he explains, there are a lot of things that you 
can control and a lot of things that you cannot control as a researcher, and it is important to 
adapt your level of ambitions to these conditions. 
5.2.1 Research ethics 
The ethics of conducting medical research in developing countries is an issue that has been 
heavily debated through the last couple of decades. Discussions often concern ensuring the 
rights of patients and individuals participating in the research. The following chapter, 
although also wishes to outline some of ethical challenges that can emerge in cross-
disciplinary and cross-cultural research where different professionals participate in and 
contribute to the research.     
Codes of medical research ethics 
A set of ethical standards for biomedical research involving humans, have been outlined in 
the Helsinki Declaration. First drafted in 1964 by the World Medical Association the 
declaration has since been revised several times, latest in 2008. The Helsinki declaration 
emphasize on the importance of protecting the life, health, dignity, integrity, autonomy, 
privacy and confidentiality of the research individual. Therefore an assessment of the risks 
and burdens for the participants should be made and should not exceed the possible 
benefits of the research. Also the research objects should be able benefit from the results of 
the research in some extent. According to the declaration, informed consent of the 
participants is also essential to ensure that participants understand the scope of the research 
and their own rights (WMA 2008: 1-2).  
Ethics in cross-disciplinary research 
Different professionals sometimes have different focuses when it comes to the questions of 
research ethics. For example whether ethical deliberations should be made from an 
individual or a bigger social perspective. Hoyer et al. has outlined some of the challenge 
that can emerge when social scientist, and people within the tradition of medicine 
   
     21 
collaborate in research projects. They suggest that conflicts between social scientists 
studying health services using medical professionals as informant involve a confrontation 
between two research ethics traditions, where the medical tradition tend to focus on the 
rights of the individual and social science tend to focus on political and social implications 
(Hoyer et al. 2005: 1747). To meet these challenges, it is important when using medical 
professional as informants, that the role of the informant is clear. Confusion regarding 
whether the medical professional is a partner of research or an object of research can create 
controversies, as the informant might experience a violation of confidence. Openness and 
transparency therefore is important when working around your informants, (Hoyer et al. 
2005: 1744, 1747). 
As a researcher it can be helpful to be aware of these different interpretations of ethics. 
Even though social science does not have the same strong tradition of using informed 
consent as the medical tradition, some form of consent from informants should be ensured. 
Not necessarily in the classic medical tradition, but by engaging in dialog and discussing 
the type of knowledge the research aims to produce, the researcher shows respect for the 
informants (Hoyer et al. 2005: 1745-1746). 
Ethics in cross-cultural research collaboration 
When conducting research in collaboration between developed and developing countries, 
ethical challenges of this collaboration-relationship should be taken into consideration. 
Research collaborations can generate great benefits for the involved partners, but can also 
be challenged by the different agendas and opinions that often exist between collaborators.  
For partners in developing countries, who often experience widespread prevalence of 
diseases and lack of institutional resources to carry out health research, it can sometime be 
difficult to decline offers of collaborations from researchers in developed countries, 
especially in the face of ready funding. This can show to be problematic as any research 
topic proposed by partners in developed countries as a result often can be justified as a 
priority (Edejer 1999: 440). In research collaborations between developed and developing 
countries it is important to avoid ‘scientific colonialism’. Acting like a ‘Mosquito 
scientists’ who come into a country, take blood samples and fly them out, only sharing the 
results through publications, is no longer perceived as acceptable practice today. As well as 
the ‘parachuting consultants’ coming into a country for a very short period of time, and 
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quickly rehashing local information without producing any significant scientific 
contribution (Edejer 1999: 439). According to Tessa Tan-Torres Edejer, medical officer in 
the WHO, it is important to address the issue of the inequity that often exist in 
collaborations between developed and developing countries and focus on putting local 
priorities first. Ensuring that the dignity of the local people is preserved and that they will 
benefit from the research. To ensure a fair and beneficial collaboration for all partners a 
long-term perspective for the collaboration is essential and Edejer also stresses that 
development of capacity is a key component in a successful south-north collaboration 
(Edejer 1999: 440).  
  
   
     23 
6 ANALYSIS 
The following analysis aims to examine the potential of the IP-10 test in Egypt, where 
clinical investigation of the test has taken place. The analysis starts out by outlining some 
of the epidemic factors influencing TB-control in Egypt, based on information from the 
WHO and the National TB Control Program in Egypt. Using the categorization of 
Bourdieu’s capitals outlined in previous chapter, socio-economic challenges of fighting TB 
in Egypt will be sought identified based on interviews with Prof. Nabila El-Sheikh head of 
Molecular Immunology Unit at Al-Azhar University Cairo, and Asharf Abdelhassib, chest 
physician and head of the Multi-Drug-Resistant department at Abbasia Chest Hospital, 
Cairo. Finally the potential benefits and challenges of an implementation of the IP-10 test 
in Egypt will be assessed in relation to the identified challenges of TB in Egypt.  
6.1 The challenges of controlling and fighting TB in Egypt 
6.1.1 Epidemiological factors influencing TB-control 
Egypt has a population of around 81 millions, with 43% of these living in urban areas. In 
2010 WHO estimated the incidence of TB cases in Egypt to around 15.000, though only 
9.588 cases of TB were reported (www.who.int). The numbers confirm that TB is still a 
health issue in Egypt. The National Tuberculosis Control Program (NTP) has been 
established by the Ministry of Health, with the purpose of effectively controlling and 
reducing TB in Egypt (NTP: 4).  
Egypt adopted the WHO’s DOTS strategy back in 1996 and the NTP undertakes the task 
of implementing the principles of the DOTS and STOP TB strategies (NTP: 5, 11). 
According to the NTP’s latest strategic plan, low detection rates as one of the current 
challenges of TB control in Egypt (NTP: 6). With a case detection rate of 64%, Egypt still 
have some way to go, before reaching the international goal of a detection rate of 84% by 
2015. But when looking at the treatment success rates though, Egypt has already fulfilled 
the aim of 87% successfully treated cases, with a current treatment success rate of 88% for 
new cases and 78% for re-treated cases (www.who.int). Asharf Abdelhassib also explains 
that rates of successful treatment in Egypt are good, but points out that the country 
experience increasing problems related to the emergence of more MDR-TB (APP. IV 
Abdelhassib: 1, 6). In 2010 MDR-TB was found in 2,2% of new TB cases in Egypt and in 
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38% of the retreated cases (www.who.int). Though there seem to be an increasing focus on 
the complications of MDR-TB in Egypt, little focus seems to be paid to infections of HIV, 
which is known to have significant influence on the prevalence and mortality of TB. 
Looking at WHO statistics the prevalence of HIV in Egypt is very low with only 1 out of 
every thousand being infected. The low prevalence can explain why it is only 47% of the 
TB patients HIV-status is known, or the low prevalence could be explained by a lacking 
focus on HIV detection. Either way the 47% is fare from the international goal of having 
85% of TB patients tested for HIV (www.who.int).   
6.1.2 Economical, cultural and social challenges 
As a part of the DOTS-strategy all TB patients in Egypt are provided with free anti-TB 
drugs and care related to determine their TB status. This obviously is an advantage for 
patients with low economical capital, and according to the NTP one of the strengths of TB 
control in Egypt. Looking at the national economical capital, 39 chest hospitals and 118 
chest clinics are spread around the country (NTP: 11). Although treatment and TB 
microscopic laboratories are available in all chest facilities, Egypt still has a low laboratory 
capacity of smear microscopy. Compared with the international goal of 1 smear 
microscope laboratory for every 100.000 capita, Egypt only have 0,3 laboratory 
(www.who.int). This combined with 57% of the population living in rural areas is likely to 
generate challenges of reaching health facilities for patients with low economic capital. 
Professor Nabila El-Sheikh is critical towards the health care system in Egypt and points 
out the lack of effective screening programs that can detect cases of TB early and cut the 
chain, as she expresses it. Also the absent possibilities to follow up on patients that fail to 
continue their treatment is something that she believes needs to be addressed on order to 
fight TB (APP. IV El-Sheikh: 2). Asharf Abdelhassib seems to have greater confidence in 
the Egyptian health care, and stresses the importance of the TB patient’s enrolment in the 
governmental treatment regiments implemented by the NTP. “If the patient works with the 
National TB Program, he will go for Cat1 or Cat2 and be treated successfully 1”. He 
explains that problems with treatment failure emerge when patients choose alternative 
methods of treatment for example in the private sector (AAP. IVAbdelhassib:1-2). El-
Sheikh believes that the governmental institutions underestimate the burden of TB in 
                                                
1 Cat 1 and Cat2 refers to the categorization of patients with drug-sensitive and drug-resistent TB. 
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Egypt. She explains that Egypt has a high prevalence of diseases like hepatitis C and 
diabetes, which immune-compromising patients in Egypt and hereby, she believes, 
enabling the emergence of TB (APP. IV El-Sheikh: 1). 
Both El-Sheikh and Abdelhassib emphasize greatly on the importance of educating people 
about TB. According to Abdelhassib health education and direct contact to the patient are 
key factor in ensuring that patients do not default the treatment (APP IV. Abdelhassib: 6). 
El-Sheikh believes that missing community education is one of the greatest challenges in 
fighting TB in Egypt (APP IV. El-Sheikh: 2). El-Sheikh and Abdelhassib also point out the 
lack of health education as the course of a widespread TB stigma in Egypt. Both of them 
explain that ignorance courses people to fear TB and hide their illness (APP IV 
Abdelhassib: 9, El-Sheikh: 4).  The NTP also recognize that TB is a stigmatized disease in 
Egypt (NTP: 5). Thus there seem to be an agreement that a large part of the population has 
low cultural capital that not only causes problem in regard to the individual treatment but 
also in the control of TB infection, as it increases the risk of spreading the disease. 
6.2 Possible benefits of the IP-10 test  
6.2.1 Epidemiological benefits 
Previous studies and preliminary data from the clinical testing in Cairo show that IP-10 test 
is performing comparable to the existing IGRAs for latent tuberculosis infections. See the 
clinical result in appendix VI. In 2008/2009 Abu-Taleb et al. evaluated the potential of 
using IGRA in Egypt against the TST. As mentioned one of the significant advantages of 
IGRA over the TST is that it is not affected by the presence of BCG vaccine that often 
course false-positive TST result. In Egypt the BCG vaccine is today mandatory for 
children (APP. IV Abdelhassib: 11), which creates a great disadvantage for the TST. Abu-
Taleb et al. conclude that the QTF performs better than the TST and correlates better with 
TB exposure (Abu-Taleb et al. 2010: 752).  
Though the IP-10 filter paper method is a test for LTBI, improved screening of contacts 
and vulnerable group for LTBI could help detect some cases among this individuals before 
they become active or in an early active stage before symptoms has occurred. Thus the IP-
10 filter paper method could have a positive effect on the low cases detection rate in Egypt. 
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6.6.2 Socio-economic benefits 
By using the filter paper method for the IP-10 test, it is possible to perform testing in areas 
with very limited laboratory facilities. This enables the possibility of increased testing and 
screening in for example rural areas, making screening of for example close contacts of TB 
patients living in these areas easier. This will also reduce travel and travel costs for people 
living fare away from more advanced health facilities. The IP-10 and filter paper could 
also be used to screen other vulnerable groups. Beside patient contacts, the NTP identifies 
refugees, TB/HIV co-infected patients and prisoners as some of the groups that should 
receive extra attention (NTP: 9-10). Though systematic screening might not be possible for 
all of them, increase screening of some of these individuals might help to control the 
infection in these groups. 
6.3 Possible challenges for the IP-10 test and unintended effects 
6.3.1 Epidemiological challenges 
The IP-10 test, as the IGRAs cannot tell the difference between latent and active TB. When 
given a positive result in the IP-10 there is therefore no way of knowing if the infection is 
in fact latent or active TB without any clear symptoms. Prof. Nabila El-Sheik believe that 
it is important to develop an effective test for latent TB, to enable more screening, but is 
skeptical about the current existing methods, as she believes they are not able to cope with 
the epidemic challenges in Egypt. She mentions the prevalence of environmental TB 
organism and non-TB mycobacteria as some of the factors that affect and mask the results 
of LTBI tests (APP. VI El-Sheikh: 4-5). Though studies have indicated that the IP-10 test 
performs better than the IGRAs in HIV patients and children, both are challenged in these 
individuals (Ruhwald et al. 2012: 176, 178-180). 
6.3.2 Socio-economic challenges 
In their evaluation of the IGRA Abu-Taleb et al. addresses the issue that IGRA is much 
more expensive to use than the TST. Although it seems to perform better the cost for the 
IGRA is 250-300 EGP2 for each patient while the cost of the TST is 15-20 EGP (Abu-
Taleb et al. 2010: 752). The high cost is partially due to the more advanced laboratory 
facilities needed to process the samples. The questions is if the filter paper methods will be 
                                                
2 EGP, Egyptian pounds. 1 USD equals 6 EGP. 
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able to bring down the costs to a sufficient level, by enabling centralization of laboratory 
analysis.   
Opening up the possibility of increase screening for LTBI, there is a number of possible 
unintended effects that should be given attention. When enabling LTBI testing in rural 
settings it is important to ensure that you have skilled health staff that is able to guide 
individual that should receive a positive test for them to know what to do with this result. 
If enabling screening to certain individuals or groups you should also be sure to have the 
resources to offer them prophylaxis treatment if given a positive result. Conducting 
screening without ensuring proper education of people in the communities where the 
screening takes place can generate more fear and stigma, why such initiatives should not 
be made without taking into consideration elements of community education. When 
making priorities of LTBI screening it is also important that these do not remove focus or 
fund from the detection of active TB cases, as these are the ones spreading the infection. 
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7 DISCUSSION 
7.1 Evaluating the objectives and methods of the internship 
The main objective of the internship has been to evaluate the clinical potential of the IP-10 
novel test in a relevant endemic setting. The original aim was to include 50-100 TB 
patients during the intern’s two months stay in Cairo. During the stay this showed to be 
impossible, only 36 TB patients and 11 controls were included in the study. This called for 
a new strategy to ensure sufficient amount of data for the study. A decision was made to 
continue the study, training an Egyptian biotechnology student to proceed the work. Thus 
the ambitions of the Danish research team showed to be too high compared to what was 
possible. At the project start no clear strategy had been made for the long-term 
perspectives of the collaboration, which had only been loosely discussed. Throughout the 
project the Egyptian partners demonstrated great cooperative willingness, though 
expressing worries of the long-term objectives of the collaboration. Although the 
insufficient number of patients delayed the original time scoop, it also opened up for a 
more furrow discussion of the long-term collaboration with the Egyptian partners. This 
together with the training of local students improved collaboration-relationship. Thus 
moving the project closer towards a fair and mutual beneficial collaboration and the 
Danish research team further away from conducting ‘mosquito research’.  
During the stay some practical challenges of ensuring efficient equipment and smaller 
misunderstanding as a result of language barrier were experience. The fact that the intern 
did not understand and speak Arabic made some parts of the coordination difficult, but in 
the end this did not seem to affect the result of the study. 
The above analysis’ examination of epidemic and socio-economic challenges of TB in 
Egypt is to a great extend based on the interview with Prof. Nabila El-Sheikh and Asharf 
Abdelhassib. These informants were chosen because they through their professions possess 
a substantial knowledge about TB-issues in Egypt. Though the informants addressed both 
different and some of the same issues of TB control, the analysis probably do not provide 
the full picture, but merely outlines some of the challenges. To achieve a more 
comprehensive understanding of the challenges of TB in Egypt, a more in depth 
investigation of TB-perception among health and research professionals and the Egyptian 
health care system could be performed. 
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El-Sheikh did not only act as informant but was also the project collaboration partner, 
which might have affected the data produced during the interview. The intern’s double role 
as a medical and international development researcher sometimes created confusion when 
explaining the scope of the clinical trial and the development study of TB respectively to 
involved partners and co-workers.  
7.2 Using the IP-10 test in developing countries – evaluating the potential of the 
test. 
Though some benefits of implementing the IP-10 test in Egyptian settings were recognized 
in the analysis, a number of challenges was also identified. It is likely that the IP-10 filter 
paper method will be able to improve the possibilities of screening and case detection of 
latent and active TB. But with a wide spread TB stigma and indications of a to some extent 
of insufficient health care system, such socio-economic issues should also be taken into 
consideration. These are issues that are also sought addressed by the WHO’s Stop TB 
Strategy.  
Further estimation of the costs of using the IP-10 filter paper method should be made. The 
predecessor IGRA has proven very expensive to use in developing countries, why it has 
not been implemented to any significant extent and thus have not yet had any significant 
influence on the TB-epidemic. Conducting further research it is also possible that the IP-10 
protein could be used in the development of a lateral-flow-device that can be used as a 
point-of-care test (Ruhwald et al. 2012: 182-183). Thus a cost-effective methods and 
initiative such as improvement of health education is important to create a convincing 
argument for the implementation of the IP-10 test in Egypt, under current conditions.  
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8 CONCLUSION  
The objectives originally set by the Danish TB research team at Hvidovre Hospital for the 
research study showed to be unrealistic to achieve within the preset timeframe. A strategy 
for the long-term perspectives and objectives was not done from the start of the project, but 
during the project more furrow discussion and agreements of the perspectives took place. 
This was beneficial for the strengthening and fairness of the collaboration-relation between 
the Danish and the Egyptian research teams. 
Currently there are no convincingly strong arguments for an implementation of the IP-10 
test in an endemic setting such as Egypt, as there are other issues that currently appear 
more important to address. Looking at a long-term perspective is it not unthinkable that the 
IP-10 test could have an effect. If a sufficient implementation of the WHO’s Stop TB 
Strategy can be conducted over the coming decade, ensuring that the aims of strengthening 
health care systems and empowering people and communities with TB is reached, it will 
make sense to increase the of focus on the diagnostics and treatment of LTBI. If the IP-10 
filter paper method at this point has shown to be cost-effective it is possible that the test 
can have an impact on fighting TB in developing countries.   
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APPENDIX I – GLOSSARY AND ABBREVIATIONS 
 
Glossaries 
Antigen: a substance that evokes the 
production of one or more antibodies 
Chemokine: small cell-signaling protein 
molecules used extensively in intercellular 
communication 
ELISA: a popular format of a "wet-lab" type 
analytic biochemistry assay, used to detect the 
presence of a substance, usually an antigen, in 
a liquid sample or wet sample. 
Incidence rate: The number of new cases per 
population in a given time period 
Point-of-care testing: medical testing at or 
near the site of patient care 
Prevalence: The total number of cases in the 
population, divided by the number of 
individuals in the population. It is used as an 
estimate of how common a disease is within a 
population over a certain period of time. 
Sensitivity: the proportion of actual positives 
that are correctly identified   
Specificity; the proportion of negatives that 
are correctly identified 
 
 
 
 
Abbreviations 
BCG: Bacillus Calmette-Guérin vaccine 
DOTS:  Directly Observed Therapy – Short 
Course 
ELISA: Enzyme-linked immunosorbent 
assay 
HIV: Human immunodefiency virus 
IGRA: Interferon-γ release assays 
LTBI: Latent tuberculosis infection 
NTP: National Tuberculosis Control 
Programme 
MDR-TB: Multi-drug resistant tuberculosis 
TB: Tuberculosis 
TST: Tuberculin skin test 
WHO: Worlds Health Organisation 
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APPENDIX II – SAMPLE COLLECTION PROTOCOL 
Protocol for inclusion of TB patient – Abbassia Chest Hospital, Cairo 
 
Patient inclusion criteria’s: 
• Confirmed TB-diagnosis 
• No more than 30 days of TB-treatment 
 
Procedure: 
- Sample collection 
• Fill in patient questioner. 
• Fill in patient name (or initials), date of birth (DOB) and date of sample collection on the 
tube labels. 
• Extract 1 mL of blood in the 10 different tubes (7 test-tubes, marked 1-7 + 3 QFT tubes) 
OBS! The tubes only contains vacuum for 1 mL blood. 
• Shake tubes thoroughly to mix the blood with the antigens.    
• ( Collect sputum for BACTEC test and MOTT test) 
 
- Sample incubation 
• Incubate the tubes containing the blood samples at 37 degree Celsius for 16-24 hours. 
• Note the time for incubation start and finish in time schedule.  
• When incubation finish, place the tubes at roomtemperature. 
 
- Samples are taken to the laboratory 
• The samples should be taken to the lab max.  2 hours after ended incubation. 
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APPENDIX III – LABORATORY PROTOCOL 
The	  Copenhagen	  IP-­‐10	  ELISA	  for	  QFT	  plasma	  111218	  
All	  reagents	  must	  have	  room	  temperature	  before	  use.	  Note	  date	  of	  assay.	  	  
	  
Start	  by	  adding	  patient	  ID	  in	  the	  ‘Patient	  information	  and	  results’	  sheet	  in	  the	  excel	  program.	  Print	  
a	  plate	  layout	  from	  the	  ‘Plate	  layout’	  sheet	  to	  guide	  the	  pipetting.	  	  
	  	  	  	  
A:	  Samples	  and	  Standards	  
1. Mix	  plate	  
a. Add	  90μL	  dilution	  buffer	  (reagent	  A)	  wells	  1A-­‐6H	  of	  the	  mix	  plate	  
b. Samples:	  Dilute	  plasma	  samples	  1:9	  by	  adding	  10	  µL	  sample	  to	  the	  appropriate	  
wells	  (see	  mix	  plate	  layout)	  
c. Standards:	  Defrost	  one	  premade	  standard	  strip	  and	  prepare	  by	  mixing	  the	  contents	  
of	  each	  tube.	  Black	  dot	  denotes	  the	  blank	  and	  direction	  from	  low	  to	  high.	  Dilute	  
standards	  1:9	  by	  adding	  and	  10	  µL	  of	  standard	  to	  wells	  3A-­‐C.	  	  
2. ELISA	  plate	  
a. Add	  70μL	  conjungate	  buffer	  (reagent	  B)	  to	  all	  wells	  in	  the	  ELISA	  plate	  
b. Transfer	  30μL	  sample	  &	  standards	  from	  mix	  plate	  to	  the	  ELISA	  plate	  using	  a	  manual	  
multichannel	  pipette,	  in	  duplicates	  (see	  plate	  layout).	  Gently	  mix	  diluted	  sample	  
before	  pipetting	  
3. Incubation:	  Cover	  ELISA	  plate	  with	  sealing	  tape	  and	  incubate	  for	  2h	  at	  room	  temp	  
4. Wash	  the	  plate	  4x300	  µL/well	  wash	  buffer,	  aspirate	  and	  knock	  dry	  on	  clean	  paper	  towels	  
	  
B:	  IP-­‐10	  Detection	  	  
5. Add	  100	  µl/well	  TMB	  One	  substrate	  (reagent	  E)	  
6. Incubate	  30	  min,	  room	  temp,	  dark	  	  
7. Stop	  reaction	  by	  adding	  100	  µl/well	  H2SO4	  (reagent	  F)	  
8. Read	  plate	  at	  450	  nm	  with	  630	  nm	  reference	  
	  
C:	  Analysis	  and	  calculation	  of	  controls	  
9. Export	  450nm	  readings	  after	  subtracting	  630nm	  reference	  to	  the	  provided	  excel	  sheet.	  
Here	  standard	  curves	  will	  be	  fitted,	  concentrations	  determined	  and	  positive/negative	  
results	  calculated	  automaticall.
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APPENDIX IV – CLINICAL RESULT 
The results below illustrates the performances of the different combinations of TB-antigens or 
mitogen in the test tubes made at Hvidovre Hospital, compared to the in production QFT IGRA 
tubes (see figure 1A in the report).  Each dot illustrates the IP-10 concentration measured in the 
blood sample of 30 patients and 5 controls respectively.  
Patients 
Control 
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APPENDIX V– INTERVIEWS 
Interview with Thomas Nørrelykke Nissen 
Date: 04.04.2012 
Location: Copenhagen 
Duration: 43 minutes 
Informant Thomas Nørrelykke Nissen (T) is a doctor, and has worked with tuberculosis in 
Tanzania. Interviewer Lena de Thurah (L), Master student of International studies at Roskilde 
University. The interview has only been partially transcribed, as only some parts of the interview 
were found relevant for the report.  
(8.28) 
L: Så hvordan har det så været at skulle arbejde med TB, og det der med at skulle arbejde i et udviklingland 
og lave et studie og snakke med nogle mennesker og sådan den generelle.. 
T: Jamen det har været meget spændende. 
L: Hvad er det man sådan mest skal være opmærksom på, når man tager afsted og laver sådan et studie? At 
det er svært eller at det tager tid eller? 
T: Altså dels at det tager tid, og det tager mere tid end man nogensinde… Altså hver gang man tænker; okay 
så gør vi det her, så gør vi det her, så gør vi det her, og det tager så lang tid, så tager det dobbelt så lang tid. 
Fordi når man så ser tilbage, okay så er der lige den der millard ting. Nå men man troede man fik svar på det 
der i dag, nå okay. Altså. Og det, nu ved jeg selvfølgelig ikke, Egypten, jeg har aldrig været i Egypten 
faktisk. 
L: Nej det har jeg heller ikke. 
T: Jeg kunne forestille mig at på mange områder fungerer det nok som mange andre ulande, men det er 
selvfølgelig en anden kultur en den tanzaniske kultur. Så man kan sige det.. det v ed jeg ikke om tingene går 
hurtigere i Egypten. Det er ikke sikkert de gør det. 
L: Nej jeg ved det heller ikke. 
T: De er nok mere hidsige. Eller jeg kunne forestille mig kommunikationen nok var noget andet. Man kan 
sige i sådan en arabisk kontekst i forhold til sådan en syd for Sahara. 
Men altså dels, så er det vel også noget med ambitions niveauet. Man kan sige at, jeg tror det er nemt 
herhjemme fra, og specielt også hvis man er vandt til sådan laboratoriearbejde, jo som virkelig; okay der kan 
du styre det hele og hvis er noget der ikke går som det skal, så er det dig selv der har lavet en fejl. Hvor man 
kan sige når man har med sådan nogle projekter at gøre, der er en masse ting man kan kontrollere og så er 
der en masse ting som man ikke kan kontrollere. Og man kan sige, man kan ikke lave det hele selv, er også 
noget man finder ud af. Man oplever lige pludselig, at man tænker man skal ned og lave en masse uha meget 
faglige ting, men i virkeligheden så brugte jeg jo al min tid på at supervisere projektet. Man kan sige, jeg tror 
jeg oplevede mig meget på en måde som den der følte ansvar for de her ting.  At hvor man kan sige at alle 
andre er aflønnet på en eller anden måde, de får deres penge, men hvis der er noget der går galt, jamen så.. 
Så gik køleskabet med alle prøverne ud. Altså hvor man kan sige, der stod jeg som ham der havde noget at 
miste på en eller anden måde. Og det gør jo at man bruger rigtig meget af sin tid på, altså åndsvage ting. 
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Hvor man tænker at man bruger sin tid på at se ting igennem for at sikre sig at ting er i orden. Udfylder de 
tingene rigtig og det ene og det andet. Alting, har I nu, nå ikke. Eller er der ting på lageret. Hvor man tænker 
okay når de tager den sidste pakke blodprøve rør, så kommer de og siger at der er ikke flere pakker tilbage. 
Nej de kommer og sige, nu er der ikke flere. Så man kan sige, hele tiden bruger man sin tid på sådan nogle 
ting og sidder jo så lige pludselig ikke særlig meget på kontoret og bruger sin uh så veluddannede hjerne til 
at lave sine ting.  
Så det bliver sådan meget. Og der tror jeg også det er vigtigt at have ambitionsniveauet til ligesom at sige; 
okay, tidsplaner kommer sjældent til at holde og der er rigtig meget projektarbejde i at arbejde i sådan en 
kontekst. Og også på den måde.. hvad var det jeg ville sige. 
Det tror jeg hvert fald, det er sådan det som virkelig sådan bonger meget ud.  
 
(12.50) 
T: Det er sådan meget, man er problemløser. Der kommer et problem og det skal man løse. Man skal have 
ting til at fungere. Og der tror det er godt at have en rolig og måske lidt kreativ tilgang til det. Så hvis der er 
noget der går glat, at så, jeg ved ikke om man ville sætte sig ned og græde, men der er noget der går galt hver 
dag. Det er meget også ligesom at sige; okay det her det er ikke godt, hvad kan vi gøre ved det? Og det er jo 
sådan, jeg tror nu længere du kommer ud på landet og specielt i ulande, jo mere fjerner man sig fra ’nu har vi 
den her protokol. Nu laver vi den her ELISA og det sekund’ hvor det hele ligesom bare kører helt tight og 
man kan lave et fint projekt og uha det hele er bare kørt på en snor. Lige pludselig, så står du bare sådan lidt; 
okay, køleskabet med alle prøverne er gået i stykker NU. Altså, så kan man sætte sig ned og græde og smide 
det hele ud og man kan også sige; okay hvordan redder vi der her bedst mulig. Og sådan er det bare hele 
tiden. At altså ja, men må ikke holde det oppe imod sådan laboratorieforskning, fordi så tænker man sådan et 
Afrika-projekt; altså det er junk. Junk, junk, junk. Men, det er jo så også omstændigheder og vel også langt 
hen ad vejen realistiske omstændigheder i forhold til hvad man kan forvente. 
L: Så situationen er bare tit meget anderledes. 
T: Helt anderledes. 
L: Og problemerne er bare mange gange.. 
T: Ja de er større og så er de af sådan meget praktisk karakter. Det er jo netop sådan et eller andet; Hov vi er 
løbet tør for det der. Altså hele tiden. Tja, så vil de have mere i løn og så siger du; jamen kan du ikke lige, 
kan I ikke også lige gøre det her? Det står ikke I vores jobbeskrivelse. 
 
(15.45) 
L: TB, hvis vi skal snakke lidt om det. Nu ved jeg godt at du sikkert ikke har den store forkromede løsning 
på hvordan vi løser problemet. Men hvad er det du, med dit ophold og den erfaring du har med det du har 
oplevet har været de store problemer omkring TB. Og hvad har været udfordringer? Hvorfor er det vi ikke 
har formået at løse det her endnu?  
T: Det er jo mange ting. Problemet er jo at man dør af det i tredje verdens lande. Så man sige det er jo et stort 
problem også i forhold til behandling. HIV efterhånden slår jo færre og færre ihjel, men specielt i tredje 
verdens lande, hvor HIV-behandlingen måske kan halte og folk så får TB. Jamen der er jo rigtig mange der 
dør af en ikke særlig sexet sygdom. Så på globalt plan er det en lidt nederen sygdom at få.  
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Så behandlingen af tuberkulose er jo, det er jo tungt. Det er seks måderne på antibiotika, og det er vigtigt at 
du holder kompliance. Det er jo næsten umuligt. Selv i Danmark, kan man jo dårligt nok få patienter til at 
tage penicillin i 10 dage, fordi at efter tre dage når du føler dig rask, jamen så går det ikke. Så behandlingen 
er svær. Og når du først har diagnosticeret dem, så behandlingen er svær. Man kører de der DOTS, directly 
observed treatment short-course. Hvor de får et kursus og kommer på TB klinikken hver dag i den første tid, 
og så en gang om ugen.  
L: Hvor tit kommer de der for at få behandling? 
T: I starten kommer de dagligt og man kører sådan et internationel standardiseret kursus, som de kører og de 
underviser dem, hvor de i starten kommer dagligt og så jo længere de kommer i forløbet jo sjælnere og 
sjældnere, hvor så typisk, i Tanzania er der sådan nogle TB-klinikker, der er spredt ud i landet. Hvor de så 
kommer derhen og bliver fulgt. 
L: Okay, som er lidt mere lokale og tættere på landsbyen? 
T: Ja præcis. Så de ikke nødvendigvis skal tage hele vejen. Det er jo så for dem der er blevet diagnosticeret. 
Og diagnosticere, specielt ved børn er stort set umuligt. Deres immun respons er så lille, hvor voksne der er 
bacillerne i deres spyt. Hos børn, de får slet ikke dannet den infektion så kraftigt i lungerne. Så det er vildt 
svært at diagnosticere det som man gør med voksne.   
 
(19.15) 
Man kan sige i tredjeverdens lande hvor  man lever meget tæt sammen og  bor sammen, sover sammen, 
dårlig udluftning så er det jo smitte via luftveje. Så det er jo også på den måde noget som ligesom optimere 
smittevejen.
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Interview with Asharf Abdelhassib and Faten Aly Shoukry  
Date: 11.07.2012 
Location: Abbasia Chest Hospital, Cairo 
Duration 42 minutes 
Asharf Abdelhassib (AA) head of MDR-TB department at the Abbasia Chest Hospital acted as the 
main informant. Doctor Faten Aly Shoukry (FAS) head of laboratory at Abbasia Chest Hospital, 
only participated in some parts of the interview. Interviewer Lena de Thurah (LDT), Master student 
of International studies at Roskilde University. 
 
LDT:  
Yes I have some questions, that I would like to ask you for me to understand better about tuberculosis in 
Egypt and for me to be able to understand how we can you the new test and if we can use the new test. 
(FAS excuses herself, as she has to go and talk to the Hospital Director) 
LDT:  
So I have some general question about tuberculosis in Egypt and then I have some more specific questions 
about your experience with TB here in the hospital. So my first question is actually: In your opinion is TB a 
big problem in Egypt? Do you have a lot of TB in Egypt? Do you see it a lot? 
AA: 
Yes, I think TB is a more developing problem, the problem is increasing right now, because of the problem 
people defaulting the treatment. Especially for the problem of MDR. MDR emerge from TB because many 
patients default the treatment during CAT1 or CAT2 they stop. They start the treatment and then they stop it, 
or have regular treatment and, or have treatment outside the system our system here. Our system for Cat1 
and Cat2. In the private sector they may take regular treatment or improper treatment. 
LDT: 
What is Cat1 and Cat2? 
AA: 
This is category 1 treatment. This is for… First of all I have to tell you that we divide according to that 
treatment in drugs-sensitive TB and drug-resistant TB or MDR. For drug sensitive TB we use Cat1, we use 
four drugs for two month then continuation for four month by two drugs. While for Category 2 we use five 
drugs especially ‘Salinder’. Five drugs initial for two month, then four drugs for one month, then three drugs 
for five month. This is Cat1 and this is Cat 2. I am speaking about the treatment. We have drug sensitive and 
drug resistant. The problem is that many patients may drop the treatment when they start. They start Cat1 
and then after two or three month they drop the treatment. And Cat2 they start and drop the treatment. So we 
have an emerging problem of Multible Drug Resistance. In my point of view this is the problem in Egypt. 
LDT: 
Okay. So in your opinion that means that you have more tuberculosis in Egypt right now. 
AA: 
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More, especially the bad one, the MDR. So, you can write: The emerging problem of drug resistant 
tuberculosis. This is the answer. This is my answer. And this is related to the improper treatment. Related to 
the patient and the private sector. Private sector may give drugs, not efficient for TB. Okay?  
So some patients may have treatment for TB in the private sector, they don’t work on the system we are 
working with here. 
LDT: 
Okay, so they don’t work on the same program as you do? 
AA: 
No no no. They may give drugs three drugs or two drugs instead of four or five. So we have the system here 
in the hospital if the patient is admitted here he will go to the system Cat1 or Cat2 or what ever his category. 
So.. 
LDT: 
Yes because you have the National TB Program? 
AA: 
National TB Program. If the patient works with the National TB Program, he will go for Cat1 or Cat2 and be 
treated successfully. But outside the private sector, or event in the system itself, maybe sometime the patient 
at the dispensary will start the treatment and then after the symptoms are improving he will drop the 
treatment. So this is the problem. We have a problem of defaulting the treatment. We have a problem, an 
emerging problem of MDR. 
LDT: 
So in your opinion the greatest challenge to fighting TB in Egypt, is that making the patients take the drugs 
or is there other… What is the greatest challenge? 
AA: 
Not all the patients go to the system. Not all the patients. 
LDT: 
Is this the greatest challenge? Is this the biggest problem right now? 
AA: 
It is one of the problems that causes MDR. This is one of the problems. 
LDT: 
So the strategies used in Egypt to fight TB and control it is the National TB Program. 
AA: 
The system yes. This is the system. If the patient go to the system it will have according to the system patern 
or categorization of the patient Cat1, Cat2 or second line treatment according to the sensitivity of the TB. 
LDT: 
And this National TB Program does it follow the WHO… 
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AA: 
Yes yes, it works exactly on the WHO guidelines, for drug-sensitive and for drug-resistant. 
LDT: 
Okay. So all the treatment in the National TB Program is exactly… 
AA: 
Exactly the same as. And that is why the speaking above. If the patient will go to this system, it will be 
successfully cured. But if he go outside, with the private sector, or sometime will go to the system but not 
continue. You will see the problem with defaulting, the problem of resistance. 
LDT: 
I see. Good. So how many TB patients do you have here in the hospital a year or a month. 
AA: 
We have about 17/70 patients per 10.000 for TB. Among them we have problem of MDR in 50 percent of 
the patient in 2. Cat group. 
LDT: 
50 percent of the patients that comes here? 
AA: 
No no, not 50 percent. For those who have drug-sensitive TB, some times will develop about point five 
percent of them in Cat1 will develop MDR. And about 20-40% may develop MDR in the Cat2. You 
understand Cat1 and Cat2? 
LDT: 
Yes I understand. 
AA: 
Cat1 for the new cases and Cat2 for the relapse or chronic cases. 
LDT: 
Yes, the ones that are coming back. 
AA: 
Yes. (…) For Cat1 about point 5 percent of them may develop MDR. And for Cat2 from 20-40 percent may 
develop MDR.  You know what is the meaning of MDR? 
LDT: 
Yeah MDR is Multi Drug Resistance. That makes it very difficult to treat and very expensive also. 
AA: 
Yes very expensive and long duration treatment, it may prolong it for two years. 
LDT: 
So the system, this is a referral hospital. So how does the system of referral work? Do you get patients from 
small clinics outside Cairo? 
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AA: 
The patient will be diagnosed first in the TB-centres in the country and by direct smear and x-ray. And then 
the patient will be send in the NTP and then from the NTP to the referral hospital here in Abbasia Chest 
Hospital and other hospitals in the governorates around Egypt. 
LDT: 
So they have already been diagnosed with TB when they come here? 
AA: 
Yes, they will be diagnosed on the outside, according to the criteria of diagnose by direct smear, with at least 
two direct smear positive or culture, one culture positive. Or x-ray have symptoms and signs. Like this, and 
then the patient will be send from the dispensary to the NTP, from NTP to our hospital. 
LDT: 
And this is where you give them the treatment then? They don’t receive the treatment in the TB-centers? 
AA: 
According to the situation of the patient. We divide the patients here, when the patient comes here, they will 
be divided into drug-sensitive and drug-resistant. These are different pathway. For drug-sensitive the patient 
will go on DOTS. What is the meaning of DOTS? The patient directly observed treatment in the TB-center. 
Not in the hospital. Except for bad general conditions. Some patients may have bad general conditions, may 
have severe (…), very bad general conditions, (…) failure, needing hospitalization. But for drug sensitive TB 
the regiment is to receive the treatment in the dispensary or the TB-center. By directly observed treatment 
every day, this is DOTS. While for the resistant, drug-resistant TB or MDR the patient, our policy is to 
hospitalize the patient as much as we can. Initially we hospitalize the patient at least till the end of what we 
call the initial face or the injectable face. Because we use injections, some injections (…), injectable drugs 
(…). It is the most important drug in drug-sensitivity. So the patient has to be kept in the hospital till the end 
of this injection. It may prolong it up to nine to ten month. Hospitalization. 
LDT: 
But this is only patients who have some drug resistance. 
AA: 
No all patients. Drug resistance has to be hospitalized in the end of the injectable face. You understand this? 
LDT: 
The patients who are not drug resistant or don’t have complications, they will go outside and have the… 
AA: 
We call it drug-sensitive TB patients; DOTS outside. While drug-resistant; hospitalization till the end of the 
initial face or the injectable face. Its about from six to nine or ten months. And then outside till the end of 
treatment 
LDT: 
Okay good. So the drug-sensitive patient you see them here but they receive the treatment in the TB-centres. 
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AA: 
Except for bad general conditions. 
LDT: 
Okay yes, so people who are very weak or.. 
AA: 
Very ill and need hospitalization, needs ICU or what ever like this. They have to be in the hospital. Why? 
For the drug-resistant TB hospitalization  (…). 
LDT: 
Okay. Thank you. I just need to see where I am. Yes, and the methods you use for diagnosis is? 
AA: 
It is different. It is different for drug-sensitive and drug-resistant. First of all I will tell you, we divide them in 
drug-sensitive and drug-resistant. This is the base. 
LDT: 
How do you do that? 
AA: 
By the culture. Okay, for the drug-sensitive TB the patient is diagnosed by direct smear, culture, x-ray and 
general conditions. Sometimes when we may start the treatment for the patient even the direct smear and 
culture are negative, we can start putting the general conditions of the patient. And sometimes the patient 
may have extra-pulmonary TB. There is no sputum to be produced. Okay. We then diagnose them according 
to the criteria by WHO. 
This is for drug-sensitive TB. For drug-resistant TB, this patient. Only the culture… 
(AA’s phone rings – he excuses himself and takes the call) 
AA: 
Okay, for drug-resistant TB they should be diagnose by DST, DST is drug-sensibility testing. Drug 
sensibility testing for the first line of anti-TB drugs, by the only reliable and reproducible lab in Egypt, which 
is the national reference lab. This is the only reference lab we depend on the culture for DST for MDR, it is 
the national reference lab. Okay? It’ the lab  of the health ministry. This is the only lab we depend on. This 
lab by direct smear, the culture, by direct... sorry by DST of the culture will show that the patient is resistant 
to at least (… ) and (…) together and so this patient is MDR patient by drug sensibility test. The patient will 
be send from the reference lab to the NTP and from the NTP to our hospital here. 
LDT: 
Okay. So most diagnostics take place in the TB centers, before they come here? 
AA: 
Yes yes.  
LDT: 
So here at the hospital you don’t do the diagnostics after you get the patients… 
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AA: 
Except if the patient will come here first.  
LDT: 
Okay. You have some coming directly here. 
AA: 
Yes and they are diagnosed here by direct smear or culture and then we start treatment immediately. 
LDT: 
How many come directly and how many is referred? 
AA: 
I don’t have the numbers. You can ask about this for NTP. But I think that most of the patients come from 
the outside from the TB centers.  
LDT: 
Okay, so most are referred. 
AA: 
Yes they are referred from outside. 
LDT:  
Okay. So how many of the patients in your experience complete a successful treatment? 
AA: 
For what? For MDR? I am head of MDR so I am speaking about MDR. If we speak about MDR we have 
what we call final outcome of the patient. This is the final outcome of the patient.  
So we dived them into cured, complete treatment, defaulted, death and treatment failure.  In Egypt we have 
about combined complete treatment, combined cured 68-69 percent of the patients. 
LDT: 
For MDR? 
AA: 
For MDR yes. Cured and complete treated. Both together considered successfully treated. But we have 
difference between cured and complete treatment. This depends upon the cultures, negative culture. The 
patient has in last year of the treatment. If the patient has at least five culture in the last year of the treatment, 
all of them are negative. This patient is considered to be cured, but if the patient has less than five cultures in 
the last year of the treatment all of them are negative this patient is considered to be complete treated. If the 
patient has at least one culture in the last three cultures in the last year of the treatment, this patient is 
considered to be treatment failure. We call it medically fail. And if the patient stops the treatment for  more 
than two months, continuous two month during the treatment for unknown reasons,  this patient is considered 
to be default. 
LDT: 
Okay I see, and do you know, how about the TB drug-sensitive patients? 
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AA: 
No I don’t have the statistics about the drug-sensitive. But I am speaking about MDR. 
LDT: 
Yes I understand. So in your experience with the patients, what is the most important thing for the patient to 
ensure that they get a successful treatment? Is there anything that you can see? Some patients doing 
something wrong or some patients doing something really good that are making them succeed in the 
treatment? Or somebody that are making them fail? 
AA: 
I think that the health education and the direct contact with the patient is very important. And this is the true 
importance of the hospitalization. Especially in Egypt and in cultures like Egypt because we have most TB 
patient in Egypt and Arab countries are very low standard patients. And these patients have to be kept in the 
hospital for health education. To be health educated directly by the doctor in the ward. Not outside. In the 
dispensary, the patient will go to the dispensary, receive the medicine and go outside. There is no direct 
contact. There is no close contact between the physician or the health staff and the patient. So this is the 
importance of hospitalization. In our country and in our culture it is very important. The code of the success 
we have, we have a successful results in MDR compared to developed countries. In countries in Europe the 
success rate is less than 60 percent, we have 67-68-69 percent. Why? Because in Europe they don’t depend 
on hospitalization. Once the patient is diagnosed they will receive treatment in the... I’m speaking of Europe, 
Eastern-Europe, not Western-Europe, but in countries like Latvia, Russia like this. The patient will be send 
to the dispensary immediately to receive the treatment outside the TB Centre.  And outside the patient may 
develop side effects, adverse effects from the drug, and there is no one to speak with him about adverse 
events and how to deal with it. While if the patient is kept in the hospital there will be direct contact between 
me and the patient. I will speak to him. I will show him the importance of continuation of the drugs for the 
long duration period. For MDR the patient will continue the treatment for two years. How he will go to 
continue this for two years unless there is health education from the doctor and the staff. This is the 
importance of hospitalization. I am with hospitalization as much as we can. Especially for low standard 
patients and less educated patients. Cause it is important to be in close contact with the patient and to speak 
with him about what is TB, why you are giving him – for MDR we give 15, 7 grams of anti-tuberculos every 
day. These are antibiotics. We give them one 15, 7 grams of antibiotics every day. And the patient will 
continue with this for the whole two years of the treatment. How this will come, unless there is health 
education and direct and close contact between me and the patient to speak to him about this. 
LDT: 
So these are the things that you teach them? 
AA: 
Yes every day. Every day he will come to me saying I have a problem in my leg, I have problem headache, I 
have pigmentation of the skin. These are the adverse events of the drugs. Unless there is a doctor speaking to 
the patient about the problem saying: yes okay this will happen to you, but you have to continue the 
treatment. Outside there is no one to speak about it. This is the importance of hospitalization. 
LDT: 
But hospitalization must also be expensive? 
Appendix V 
 
AA: 
No no no. I’m speaken all about MDR. All the drugs of MDR are free. The drugs come from outside by…. 
FAS: 
There is a Global Fund. 
AA: 
The Global Fund yeah support. 
FAS: 
They support the National TB Program. 
AA: 
Yes, even any investigation, any extra treatment for patient, all of them are free. 
LDT:  
Are the national TB program in Egypt is it funded by the Global Fund. 
FAS: 
All of the TB 
AA: 
No no but for MDR it is. 
LDT: 
I see. I did not know that. Very interesting 
FAS: 
And they give money for research work. Some research work, treatment of MDR. They choose some subject 
and this support this.  
LDT: 
Okay I see. The treatment for the patients, for the MDR it is paid by the Global Fund. What about other TB 
patients? 
AA:  
The drug sensitive TB 
(AA and Faten talk together in Arabic) 
FAS: 
You mean for ordinary TB patients? 
(AA and Faten talk together in Arabic) 
FAS: 
Drug sensitive. This is the concern of the ministry of health. They are the ones supplying us with the drugs. 
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AA: 
The government yes. 
LDT: 
So the patients them self, they don’t pay? 
AA: 
No no no 
FAS: 
All are free. All here in the hospital is free for the patient. All investigation, all. The culture etc. All free for 
TB patients. The in-patients it is free. 
AA: 
And even in the TB centers also. Till the continuation of the regiment, all investigation… 
FAS: 
The treatment is free. We want to encourage the people to come and get the treatment, cause we want to end 
this problem in Egypt. Because most of the patients in general are very poor. If you depend that he go and 
buys the drug. They will no go. So they give him the treatment in order to be cured. If it is not cured there 
will be more problem and it will spread the infection.  
(23.40) 
LDT: 
Do the TB patients express any concern regarding their illness and the treatment? Are they scared, embraced 
or… do they express anything are they worried? 
AA: 
You are speaking about the stigma? 
LDT: 
Yes also stigma. 
AA:  
Yes yes of course. 
FAS: 
There is a TB stigma. Everybody having TB, they don’t want anybody to know. 
AA:  
Especially for females. Some of them will be divorced. And they are isolated in the community. This is a big 
problem of stigma in our culture.  
LDT:  
Why is this stigma? 
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FAS: 
Because it is infectious. 
AA: 
Because TB has a bad reputation from the past. It is a not cured illness. The patient will be tuberculosis for 
all of his life. He will infect others, the contacts of him. So this is stigma. 
LDT: 
So people are afraid? 
AA: 
Yes but we are speaking to them about this. And this is the importance of health education 
From the physician and the health staff and this is importance of hospitalization.  I will continue to insist on 
this. Hospitalization in developing countries, like Egypt like third world countries is very important to 
eradicate TB.  
LDT: 
So what do you tell them to fight the stigma? How do you fight this stigma of TB? 
AA: 
I’m speaking to the patient it self to tell him this is an incurable disease it will be cured. It is an infection like 
any other infection. Like influenza, like pneumonia. But it will take time, some disease will be cured in 
seven days or five days some disease like pneumonia will be cured in one month, and some disease like TB 
will be cured in six or eight months or  two years. But it is an infection the same as. No problem. This is very 
important to tell him to minimize the problem. It is just an infection like other infections, but this infection 
needs special tools, special drugs not for other infections. This health education is important.  
Also I will ask for the patients contacts to come to me, I speak to them about how to deal with the patient. 
And this is very important. How not to speak about him, not to be harmful to him. About the infection how 
to deal with the infection is very important in using his items. Like a cup of water or anything like this. This 
will be harmful to him. This is important. 
LDT: 
So also talking to people in contact with the patient. 
AA: 
Yes especially contacts. Because many patients with TB will not speak about his disease except for his direct 
contacts only. 
LDT: 
I see, good. I know this is difficult to answer in general. But the patients and the distance to the hospital and 
the TB centers and the clinics. Are there problem with people living fare away? 
AA: 
Yes this is a big problem in Egypt. Sometimes the patient live more than 20-30 kilometer from the 
dispensaries and TB-centers. And they will have to come every day to receive the treatment in front of the 
doctor. This is a big problem. Sometime the patient will go to the dispensary every week, and he will take 
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the treatment of the hole week with him.  So here do don’t understand if the patient is receiving the treatment 
or not. If they are defaulting the treatment. And so it the importance of hospitalization, because every day the 
patient will take the drug in front of me. While outside I don’t know. And sometimes they will be living fare 
away from the TB centers. A big problem. 
LDT: 
But is people afraid of hospitalization, cause they cannot be with their family or they cannot be at home, or is 
there any problem there? 
AA: 
Yes this is a problem for the patient. But I will speak to the patient. Hospitalization for MDR. It is only for 
MDR I speak. But first I will speak to the patient from the early beginning and we will have a consent from 
the patient. This consent will be written that the patient will be kept in the hospital for at least the end of the 
initial phase or the injectable phase. Many month, from 6-8 month. And the patient will agree on it from the 
early beginning. So he will know that he will stay in the hospital for these whole months and this is for the 
benefit of him. And let me tell you that many patients accept to continue the whole course of the treatment. 
The whole two years of the treatment for MDR in the hospital. 
LDT: 
Does anybody say; no I don’t want to go to the hospital. I’m afraid or… 
AA: 
It is rare. But why? Because all MDR patients are chronic patients they have failed many times. And they are 
loosing their lives. And this is the last hope for them, to stay alive, to receive the second line treatment. So 
they will do whatever for this They will stay in the hospital for the whole course of the treatment.  All of 
patient that stay in the hospital for the whole course of the treatment, for two years, all of them are cured. 
While patients outside many off them default the treatment. And this item I speak to the patient I tell him 
from day one that we have more than 30 patients who agreed to continue the whole course of the treatment 
not only 10 months or 12 months but two years. And all of them are cured. You want to be cured like them? 
He will say; okay I want to be cured, I’ll stay for many years. This is very important. 
LDT: 
I received now 30 samples from patients. And I got a little data on the patients, the sex of the patient, if they 
have any other disease. And I can see from my data, that a lot of the patients are males. There are only two 
females from the patients I got. And a lot  of them are also smokers. Are there any typical characteristics for 
the TB patients that you see? Cause I was wondering, why are they all men? 
AA: 
No no. Female are in MDR about one third of the patients. But many females prefer to continue the 
treatment outside at the dispensary. That is why we have less number of female patient in drug-sensitive TB. 
All of them prefer to have the treatment in the dispensary outside, not to be hospitalized because of the 
stigma. Because if they are kept in the hospital all of their neighbors will know that they have TB. And it 
will be stigma for them. So they prefer to continue the treatment in the TB-centers outside without anyone 
knowing except for the direct contacts. Except when it is MDR, it is well known that the female patient had 
TB many times and had to go many times before and will be hospitalized. 
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LDT: 
Okay. So as I told you I’m working with diagnostics of latent TB and I think you working MDR, you don’t 
have any experience testing for or diagnosis of latent TB. 
AA: 
No no. For MDR we don’t depend on Quantefefon test. And I think is only diagnostic… it difference from 
tuberculin test only in BCG, positive BCG child, with positive tuberculin test. Because if it is positive and 
positive we don’t understand if this is an infection or sometime if it is an infection or not. Here there is no 
high specificity for this tool, to understand if this patient is infected or not. Because it has a BCG, and BCG 
has tuberculin test positive. If it is positive why? If the patient has a tuberculin positive and he has a 
quanteferon positive this patient is considered to be infected.  I thinks this is the important. 
(AA and FAS talk together in Arabic) 
FAS: 
Because now BCG is compulsory in Egypt. 
AA: 
If the child has BCG, the tuberculin will be positive. 
(AA and FAS talk together in Arabic) 
AA: 
If it is BCG an tuberculin it is not diagnostic here. Because BCG child continues to be positive for 5-10 
years, positive tuberculin if the child has BCG. So the difference that Quanteferon shows that this child is 
infected even it has a BCG. 
LDT: 
But in Egypt is any testing for latent tuberculosis done in Egypt? 
AA: 
No. 
FAS: 
Only the Quanteferon, they tried to introduce in Egypt, but it is very expensive for us. Because I’m going to 
do it for all contacts for example, for all medical staff. So it is very expensive for us. Tuberculin is very 
cheap. 
LDT: 
So you don’t do any contact… 
FAS: 
If a contact has a symptom, he came and we do an investigation for him, just like x-ray and sputum only, but 
we don’t have test for latent tuberculosis. 
AA: 
And sometimes maybe diagnostics for exstra-pulmonary TB, like TB in the lymph. Maybe a diagnostic tool 
but not a sure diagnosis. 
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LDT: 
Okay. Because I think, according to the WHO one third of the worlds population have the infection of the 
tuberculosis bacteria. 
AA: 
Yes they are tuberculin positive. They are infected, but not the disease. 
LDT: 
Yes exactly, they carry the bacteria. And the WHO they also say that to cure tuberculosis in all of the world 
if you want to do that, you also have to work on fighting the people who are infected but are not sick. Do you 
think that if you had better and cheaper testing for the latent tuberculosis in Egypt. That this would be helpful 
in fighting tuberculosis in Egypt. Because in Egypt you focus on the one who are sick and not the infected. 
AA: 
Yes, but also we focus on the direct contacts. We call it chemoprophylaxis for direct contact of TB patients 
during the treatment, the child in contact with his mother. Sometime we give them INH as a chemo-
prophylaxis. Also for patients who are tuberculin positive and no disease. We have what is called 
chemoprophylaxis, this is giving INH for one year for patients who are direct contacts. To the mother-baby,  
direct contact to the  mother even if it is tuberculin negative. During the treatment of his mother. And also 
for those who have tuberculin positive are not disease, and we fear that will then develop a disease. We give 
them INH as a chemoprophylaxis for one year. Because one TB patient is receiving treatment in the home, 
and close contact of this patient have tuberculin skin test positive. This contact has to receive INH for one 
year as a chemoprophylaxis not chemotherapy. This person is infected because he has a skin test positive we 
fear that he will develop a disease from infected disease, so we give them INH as a chemoprophylaxis.  
LDT: 
When you have a TB patient will you do this testing on the contacts? 
AA: 
Yes, we screen the contacts by x-ray by direct smear and by tuberculin. 
LDT: 
Is this only for the MDR or is this all TB patients? 
AA: 
No no for all TB patient. I should be for all TB patients but not done in all cases. 
LDT: 
Okay. So for all TB patients if it is done correctly, you screen the close contact. Is this people living with the 
patient? 
AA: 
The definition of the close contacts is the people living in the same home and sharing the same bathroom.  
LDT: 
So these will be screened? 
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AA: 
Screened by chest x-ray, by direct smear sputum and by tuberculin. If they have a direct contact with the 
patient during the treatment, these patients with tuberculin positive they should receive… They should! They 
should receive INH for one year. They should. But not all patient receive INH. 
LDT: 
Okay I think that was it. 
AA: 
That’s all. 
LDT:  
That was all my questions. Thank you very much. 
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Interview with Prof. Nabila El-Sheikh  
Date: 25.07.2012 
Skype call 
Duration: 29 min 
 
The interview was conducted using a skype connection. Informant Prof. Nabila El-Sheikh (N) ,head 
of the Molecular Immunology Unit at Al-Azhar University was located in Cairo and the interviewer 
Lena de Thurah (L), Master student of International studies at Roskilde University was located in 
Copenhagen. 
 
L:  
I made  a small interview guide of things I would like just to talk to you about. I think most of the things we 
discussed them and we’ve talk about them. But for me just to have it. I just started the recorder on my 
computer, so what we are discussing now I am recording. Because then I have it and can use it for my report. 
 
N: 
That’s good 
 
L: 
As I told you the questions I wanted to ask you… Well I can take from the top. Then maybe if some of them 
is not important I will just skip them. And e can just briefly go through them because I think most of it we 
discussed. It is just good for me to have it on paper or on tape or on something I can… so I am sure that what 
I write is correct. 
 
N: 
If you want to send me any piece of paper before you turn it in to the university or wanna send me some 
questions to answer you can do that. 
 
L: 
Yeah. Because the first question I have is; In your opinion is TB a big problem in Egypt? And how? 
 
N: 
Yeah I think it is though I told you that the ministry is underestimating the problem. I think it is because we 
have a lot of diseases that immune-compromise patients and I believe that we have more latent infection than 
it appears. Because we have a lot of chronic diseases like hepatitis C like diabetes like chestasomisis like 
patients on chemo dialysis, kidney problems. And all these patients are vulnerable to have TB. And they are 
not well treated. I mean they don’t have classic manifestations so it is underscored and under-diagnosed. I 
also believe that TB symptoms are not like before, which is a classic cough and weight loss and the (…) 
symptoms that we are clinically use to see in patients. Now it is not classic symptoms. 
 
L: 
Okay. Why is that? 
 
N: 
Appendix V 
 
I have no idea, but it seems like, thing are not in Egypt as it use to be. Symptoms doesn’t go as it is in book. 
So you have to investigate and look carefully. And you know the test they do in the hospital for TB is not the 
update one. So they just do smear, and not everybody is good at reading the analysis of smear. So I believe 
that they misdiagnose some, maybe I don’t know. And we still have bovine tuberculosis all though not very 
much, but we still have some circulating. And we have drug-resistant strains again, and it is not well treated. 
So there are a lot of reasons why TB is still a problem in Egypt. 
L:  
Okay I see. The patients you mentioned, the ones that have hepatitis or diabetes or illnesses like these. Do 
they get tested for TB? Is there any testing of these people? 
 
N: 
No, as you see. We don’t have a good system for health care in general for people, poor people. And you 
know they pay for all services and they can’t afford it. So, I mean there is no screening programs, good 
screening programs, there is no routine testing for kids or contacts or you know who ever have (…) 
symptoms or anything like that to pick it early and cut the chain. Because if you diagnose early you prevent 
circulation in the community. So I believe that things like that should be taken care of. But because the 
Ministry of Health they work in their own, the have a philosophy of their own and a policy of their own, and 
they don’t really listen much to other opinions. 
 
L: 
I see. When I was at the hospital they told me that thay are following the DOTS-strategy. 
 
N: 
The DOTS- strategy, yeah. It is written in the report. Everybody is using the DOTS, it is a WHO 
recommendation. 
 
L: 
Yeah. So what do you believe are the greatest challenges for fighting and controlling TB in Egypt? 
 
N: 
The challenges. I think, there is no way that you can follow up patients, there is no… I mean, the culture it 
self doesn’t help much. We don’t have the education, the health education community to keep patients from 
not continuing therapy. Because what they do is treating them until they are negative and then they go home, 
and they come just to pick up their tablets from certain centres, they designate for each patient according to 
where he lives. So these patients who not confirm to continue their therapy, nobody actually go back to them 
and say; you should. Or; where are you, why are you not picking up your medicine.  People who come for 
recurrence or you know, are those who are not taken their medicine regularly. Because it is a long therapy so 
if you don’t have the education. Why it is long, why should we stick to it and these things. And unfortunately 
in Egypt there is lack of community education health wise. So most of the poor people are not health 
educated. 
 
L: 
Okay. Community education. What does that mean exactly? 
 
N: 
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Community education is like you simplify things to let everybody aware that this disease is diagnosed by this 
and this. And treated by this and this and should be continued therapy other wise it will make harm to your 
family or to your self. You educate people, you educate the community. The private sector and the charity 
and the organizations usually in the community do that. But here there is nobody taking care of community 
education health wise. 
(10.08) 
L: Okay. So is it like making campaigns and posters about TB? Or is it going out to people? 
 
N:  
Yeah either that, or educating those who doesn’t read and doesn’t write. People go and talk to them in the 
village or in the TB centre or in the public radio. 
 
L: 
Okay, I see. So what do you think needs to be done if we want to fight TB in Egypt. What is the most 
important thing then? 
 
N: 
Yeah I think the diseases that are chronic is related in a way. And how to avoid… And good hygiene of 
people who cough - what to do. People have these symptoms - what to do. I believe community education is 
very important. It is not only in TB, but I see that with hepatitis C as well. Because, why we have high rate 
of hepatitis C, because there is no community education again. So they keep, not good hygiene, of using 
other people toothbrush maybe between sister and brother or using razors. Things like that, that can transmit 
the disease without knowing.  
 
L: 
Okay I see. You said that government in Egypt underestimates the burden of TB. Why is it that you believe 
that they do this? 
 
N: 
At the time we had a minister that, he was a professor of chest diseases and he, I don’t know why, he refuse 
to admit that we have a problem.  And I think it is again culture. Here each minister wants to say that he is 
keeping everything under control and diseases are getting down and no problems here or there. So it is a 
habit in non-democratic countries. It is the culture again. And they do not believe the publications that come 
from outside the ministry. If I for example have a published paper saying that we have drug resistance of 
such percentage, prevalence of drug-resistance. They do not consider that, they have to do their own research 
and bring their own results and God knows how they do it. Usually there is this discrepancy between what 
most of the scientists say and what the ministry says. 
 
L: 
Okay so there is a difference between the scientist and the ministry? 
 
N: 
Yeah. 
 
L: 
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Okay. Does this mean that… If you look at the official numbers from WHO for tuberculosis in Egypt it says 
that, I think last year there were around 10.000, just under 10.000 registered  cases of TB. Do you think this 
number is too small? 
 
N: 
You can tell from the number you have taken in one month or two month or whatever. If you ask Faten, it 
was out of how many she saw. That will give you a ruff idea. Because she will never see a 2000 patient for 
example in a month. So I don’t know how they get this statistic. But I know that the chest hospital is a 
reference hospital. But again, to me, I don’t know I might be wrong, but to me I know from the number of 
cases that are new, still new cases coming to the chest hospital  in one month is not less than maybe 20. In 
your hand you find that right? 
 
L: 
Yeah. 
 
N: 
So how come. You get 20 new cases in one month. And it is only one cases to 10 by the power of five as the 
ministry says. That’s how I interpret things. But really I’m not sure that, and I can not say that what the 
ministry do or say is wrong. But I have a feeling that it is underestimated. 
 
L: 
Okay I see. You also told me that stigma and TB is a problem in Egypt. Could you elaborate a bit on that? 
 
N: 
Stigma? What is a stigma? 
 
L:  
Like people being afraid of TB. You told me that people will be afraid of people that are carrying the disease 
and not talk to this person or… 
 
N:  
Well here people again because of low education level they are afraid to say that they are sick. Because if 
they are sick they believe that the girl will not married or the boy will not get a good job. So they try to hide 
that they have a chronic disease. So they are not actually open about that. And again, you go around 
practising your normal activities and nobody is aware that you have TB, so nobody is taking any 
percussions. And you see the traffic how busy it is. So a cough in one bus will get all people (…) And even 
in the street. It is heavy traffic and heavy population. And spreading in a polluted air like Cairo air, easily. 
 
L:  
Okay. Latent TB. Is anything done today in Egypt to fight latent TB infections. 
 
N: 
Not really. Nobody has even studied the latency in children and contacts in a larger scale study and estimated 
the problem, to my knowledge. And there is no, as you know, any sort of test. (TID1)Because the tests 
available is not good enough for latency in a country like Egypt. Endemic. Because abroad you can rely on 
skin testing, you can rely on clinical, you can rely on a lot of like the Quanteferon test for example. In Egypt 
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the picture is different. I just had a paper send to me, and he used skin testing and he used Quanteferon, and 
comparing. And he reported that there is latency based on the, there is no symptoms, because these tests are 
positive. And I turned it down, I rejected it because I’m not convinced that skin testing, doesn’t work in a 
country like Egypt, where you have endemic tuberculosis. Plus other environmental TB, non tuberculosis. 
That cross-react and give positive testing, because of the pollution in the air. 
 
(20.30) 
 
L:  
And also the Quanteferon test it is also difficult to use? 
 
N: 
Yeah it is the same principle. I have one thesis done in children of contacts, which I was telling you about, 
and we got some positive of non-tuberculosis kids of families non-tuberculosis. Again because of BCG 
vaccination, which is taken early. Because here they give vaccine the first month. So you have three different 
things that mask the condition. So I think we need very much a test that work in Egypt, or works in a country 
that is having environmental TB organism, non-TB organisms. And have high rate of infections and high rate 
of contact, high exposure rate and BCG in the same time. The picture is not like, you can not apply what 
CDC in America says or what you in Denmark have if you got a positive skin test or a positive Quanteferon 
that means exposure right away or infection latent right away. It is not that easy. And also again if you rely 
on clinical, again this is not good enough. Because chest x-ray, and reading a chest x-ray and having 
clinicians capable to diagnose by just x-ray is not enough. You have to have another test done to indicate that 
there is inflammation in the lung and there is somehow clinical support or clinical diagnosis that supports the 
infection. 
So it is important, but I don’t know how to answer the question. 
 
L: 
Okay. Do you think, if it was possible to develop a diagnostic test that could be used… or if you could 
develop better and easier to use diagnostic tests for  latent TB. Do you think it would make a difference in 
Egypt? 
 
N: 
Sure. I was talking to Morten and I told him, long time ago I submit that I would like to work on this in a 
project. And I really still want to do that, because it is really important for the school kinds and for the 
contact of farther and mother. Because in the poor areas you have like a family of six or seven living in one 
room, an with them are the grand parents and sometime, most of the time one of them have TB. So the 
exposure rate is very high, and there is no way that you can screen the kids or know that they have… I think 
this is one of reasons why TB is circulation in an endemic… This helps in the (…) of tuberculosis I think. 
 
L: 
So it is important to… 
 
N:  
It is important, but you have o work on that in a professional way and develop an assay for latent infection. 
Because I don’t think that Quanteferon as it is, the one that is used know, it is used in Egypt, this paper I told 
you about is done in a private lab. And this person did this study, translating what is in the pamphlet of the 
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kitt. This is not good for Egypt. These is something good Europe or America but not in Cairo. And you have 
to have a special test, a test that is designed especially for the culture here and for the conditions here.  
 
L: 
So if it was possible to develop a test it would make a difference in fighting tuberculosis in Egypt, if you 
could actually detect latent infections. 
 
N: 
Yeah sure. 
 
L: 
Okay good.  (casual talk) We talked a lot also about doing research  in Egypt. That doing tuberculosis 
research in Egypt is actually sometimes difficult because you told me the government doesn’t…  
 
N: 
Yeah because you have to take a lot of approval from the ministry and it is not easy because if you don’t 
have this agreement before, the one set for Abdel-Rahman, we couldn’t have taken the samples. It takes a 
while, and it is not easy to convince them, especially if they know that this is a project. 
 
L: 
Okay? 
 
N: 
So they might give okay for somebody to study a paper or thesis or a young researcher to do something. But 
if they fell that it is a project, then they need a lot of money. 
 
L: 
I see, and that is the ministry of health? 
 
N: 
Yeah. To give from the top to the… You know everybody working in an office of infectious diseases, till the 
periphery hospital, till the periphery administration, you have to be part of it and this complicated 
everything. Because nobody is satisfied and usually the project is limited. Percentage of salaries is 20 % 
maximum or 25 % maximum. So I usually end up having difficulty. As you see I rely on my personal 
communication with people and usually do that even for my students. Get them approval as a thesis or paper. 
 
L: 
So this is the easiest way for you to do research? 
 
N: 
Right and especially I heard that the ministry now has put new regulation for studies that, fase two and fase 
one study with the collaboration of the ministry. Because they noticed that a lot of countries come for… just 
like the project that Morten and I are trying to do hepatitis C. So I’m sure that if we got it, it would be the 
same problem. 
 
L: 
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So the problem is if you actually do research project, the ministry wants you to pay some… 
 
N: 
(…) and being a part of it means a lot of money plus a lot people work with me and a lot of bureaucracy and 
they put their nose in everything. Usually they have their own ways so I don’t really like working with them. 
But we have to. 
 
L: 
Yeah, I see. And also you told me for the government, a lot of research is not a priority for the government. 
And it is not a priority to put money into research. 
 
N: 
Well yeah. It depends on the minster actually. Usually, like the example I gave you, if the new minister 
which I think there is one coming from faculty of medicine at Cairo university. It depends on how he feels 
about the problem. Because if the people we have with the minister we have a vice-assistant especially for 
infectious diseases. So if this person see that TB is important, then TB is important. If he doesn’t see that this 
disease is important, then it is not important. It really depends of the view of the person. So the new minister 
and the new staff coming, I don’t know how they put TB. Is it a priority or? So fare hepatitis C is on the top 
of the list not TB. 
 
L:  
Okay, I see. I believe I’ve been told that the national TB program, they receive some money from  the Global 
Fund to Fight tuberculosis, HIV and Malaria. 
 
N: 
Yeah they have  a lot of money. 
 
L:  
And they receive some money also for research. Is that correct and can you apply for any of these research 
funds from the national TB programme? 
 
N: 
Well as I told you, they don’t actually do any research at the level of laboratory. When they have money, 
they have it for clinical research. Screening, treatment, reporting, follow patients things like that. So they 
care about control. But they don’t care for example for making genotyping or to for example see the 
transmission. By genotyping you can tell it’s the same strains transmitted from this person to this person. I 
don’t think they care about that. They don’t go into pure science research. But they have a lot of money 
yeah. 
 
L: 
Okay. Well I think you answered all my questions, so right now I don’t have any more questions for you.   
 
 
